Market Insights

Zai Lab and Boehringer Ingelheim have partnered to develop DLL3-targeted dual therapies for ES-SCLC and NEC. The collaboration combines Obrixtamig and Zai Lab’s DLL3 ADC, spotlighting DLL3 as a key target and nanobody technology’s transformative role in antibody drug development.

Recently, nanobody applications in oncology have achieved a major breakthrough: JSKN016, a bispecific ADC independently developed by Alphamab Oncology, has dosed its first patient in a Phase III trial. This milestone signifies that nanobody‑enabled innovative drug R&D has entered a critical phase, highlighting the clinical value and application potential of nanobodies.

A Chinese team’s latest study in Nature Communications developed BA2-1A10, the world’s first potent broad‑spectrum bispecific anti‑Ebola agent based on camel nanobodies. It overcomes the single‑strain limitation of conventional antibodies, shows excellent efficacy in vitro and in vivo, and highlights the great potential of nanobodies.

Solid tumor innovative therapy advances: US FDA approves IND for injectable HDM2024, an EGFR/HER3 dual-target Bs-ADC. A Phase I trial for advanced solid tumors will launch in the US. The drug’s unique dual-target synergy brings a new option for drug-resistant solid tumors, and this article analyzes its core mechanism and clinical value via target interpretation.

In March 2026, the Chinese innovative drug sector received exciting news — MWX401 Injection, an independently developed small interfering

A recent international team reported in Nature Communications the first mGlyR-targeting nanobody Nb20. Intranasal administration showed rapid, potent, and long-lasting antidepressant effects in mice, validating mGlyR as a novel target and establishing a new paradigm for treating neuropsychiatric disorders with nanobodies.

PD-1 immunotherapy is a classic cancer paradigm but limited by low response and resistance. PD-L1 has emerged as a core next‑generation immunotherapy target. Nanobodies, combined with 2026 advances, are overcoming clinical bottlenecks. Here we review PD-L1’s value, latest progress, and how nanobodies unlock its full potential.

Despite advances in vaccines and antivirals, respiratory viral infections remain a global challenge due to insufficient mucosal protection. A recent Nature Nanotechnology study presents mucus-tethered bispecific nanobodies that block viral invasion and enhance mucosal immunity as a novel defense strategy.

A recent Nature Communications study reports a breakthrough nanobody NB5 that specifically binds and activates the HCN4 channel extracellularly. It offers a new therapy for cardiac pacemaking dysfunction and uncovers a non-canonical gating mechanism that revises traditional HCN channel understanding.

Current FEVR treatments (laser, surgery) only relieve complications without correcting fundamental vascular developmental defects, and causal therapies are absent. In 2024, Boehringer Ingelheim licensed the FZD4 agonist SZN-413 for up to $599 million, validating the target and opening a new direction for ophthalmic disease therapy. We next introduce the FZD4 target

Yes-associated protein (YAP) is an oncoprotein that exists in an inactive form in the cytoplasm. As a key effector of the Hippo signaling pathway, it plays a central role in cell proliferation and differentiation regulation. Its abnormal activation drives tumorigenesis and is closely associated with tumor malignancy, recurrence, metastasis, and chemotherapy resistance.

CD19 is a B cell‑specific type I transmembrane glycoprotein of the immunoglobulin superfamily, expressed throughout B cell development but lost in plasma cells. It forms a co‑receptor complex with CD21/CD81 to boost BCR signaling, activating Lyn and downstream molecules, lowering B cell activation threshold and enhancing immune responses.